Beacon launches Enzalunix to facilitate prostate cancer treatment

Enzalunix is a hormonal therapy which is indicated for metastatic castration-sensitive prostate cancer (mCSPC), metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).

Beacon, one of the leading oncology drug makers in Bangladesh, will promote Enzalunix in 40mg form and each commercial packet will contain 120 tablets. The company launched the product only for export purposes.

The company authorities believe that the new product will enrich the product chart and will uphold the image and reputation of the company in the global market.